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BACKGROUND: We surveyed the occurrence of physical symptoms among long-term gynaecological cancer survivors after pelvic
radiation therapy, and compared with population-based control women.
METHODS: We identified a cohort of 789 eligible gynaecological cancer survivors treated with pelvic radiation therapy alone or
combined with surgery in Stockholm or Gothenburg, Sweden. A control group of 478 women was randomly sampled from the
Swedish Population Registry. Data were collected through a study-specific validated postal questionnaire with 351 questions
concerning gastrointestinal and urinary tract function, lymph oedema, pelvic bones and sexuality. Clinical characteristics and treatment
details were retrieved from medical records.
RESULTS: Participation rate was 78% for gynaecological cancer survivors and 72% for control women. Median follow-up time after
treatment was 74 months. Cancer survivors reported a higher occurrence of symptoms from all organs studied. The highest
age-adjusted relative risk (RR) was found for emptying of all stools into clothing without forewarning (RR 12.7), defaecation urgency
(RR 5.7), difficulty feeling the need to empty the bladder (RR 2.8), protracted genital pain (RR 5.0), pubic pain when walking indoors
(RR 4.9) and erysipelas on abdomen or legs at least once during the past 6 months (RR 3.6). Survivors treated with radiation therapy
alone showed in general higher rates of symptoms.
CONCLUSION: Gynaecological cancer survivors previously treated with pelvic radiation report a higher occurrence of symptoms from
the urinary and gastrointestinal tract as well as lymph oedema, sexual dysfunction and pelvic pain compared with non-irradiated
control women. Health-care providers need to actively ask patients about specific symptoms in order to provide proper diagnostic
investigations and management.
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With increasing numbers of long-term gynaecological cancer
survivors, the prevention and alleviation of late side effects after
treatment have become a priority. A significant number of these
survivors have been treated with pelvic radiation therapy.
Radiation therapy may induce pathophysiological changes in all
normal tissue or organs within the irradiated volume, which in
some cases will lead to symptoms negatively affecting daily
activities and quality of life. Although some late effects from
normal tissues have been extensively explored (Eifel et al, 1995;
Grigsby et al, 1995; Creutzberg et al, 2001; Nout et al, 2009), others
have been less characterised (Bentzen et al, 2010).
The mechanism leading to radiotherapy-induced late side effects
is multifactorial. Irradiation may induce direct cell killing through
DNA double-strand breaks. However, the interaction of ionising
radiation with normal tissue also induces activation of cytokines
and growth factors leading to a risk of fibrosis with decreased
elasticity and compliance and increased risk of strictures. In
addition, impaired function in blood- and lymph vessels along
with neural damage may enhance the effect (Denham and
Hauer-Jensen, 2002; Bentzen, 2006; Hauer-Jensen et al, 2007).
Severe acute side effects have also been associated with
consequential late effects in normal tissue (Dörr and Hendry,
2001). Together with patient characteristics, such as smoking,
co-morbidities and genetic factors, these radiation-induced effects
may lead to changes affecting specific physiological functions
(Andreyev, 2007; Bentzen et al, 2010).
Radiation oncologists have a long tradition of recording late
toxicity after cancer treatment. Several instruments exist, for
example, the Franco-Italian glossary (Sinistrero et al, 1993), the
RTOG/EORTC late radiation morbidity scoring schema (Rubin
et al, 1995), the SOMA-LENT system (Mornex et al, 1997) and
CTCAE (Trotti et al, 2003), but many of these combine multiple
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signs and symptoms into a single grade leading to loss of
specificity. Only rarely have the toxicity scales been developed with
guidance from the survivors. In addition, the great variety of study
designs and measures of quality of life used in studies of
gynaecological cancer survivors may make comparisons difficult.
Although many of the questionnaires commonly used in clinical
trials have been validated, for example, the FACT (Cella et al, 1993)
and EORTC QLQ (Sprangers et al, 1993) questionnaires, these do
not explore the impact of each specific symptom on daily activities
(Steineck et al, 2002).
Personal identity numbers and official population-based regis-
ters in Sweden covering all Swedish citizens offer exceptionally
good conditions for studying cancer survivors without selection-
induced problems. We performed a population-based cohort study
on gynaecological cancer survivors concerning late symptoms after
pelvic radiation therapy. We used a validated study-specific
questionnaire in order to cover specific physical symptoms,
sexuality, psychological dimensions and their impact on social
functioning since no standardised existing instruments measure all
these aspects. Here, we present self-reported symptoms from
irradiated normal tissues, that is, the anal sphincter, the bowel, the
urinary tract, the pelvic bones, the lower abdomen, legs and
symptoms related to sexuality among gynaecological cancer
survivors and compare their occurrence with that of population-
based control women. In addition, we present a detailed
description of the demographic and clinical characteristics and




A cohort of 1800 women treated with external pelvic radiation
therapy alone or as part of combination therapy for a gynaeco-
logical malignancy was identified. The women were consecutively
treated between February 1991 and December 2003 at Radium-
hemmet, Karolinska University Hospital in Stockholm or at
Jubileumskliniken, Sahlgrenska University Hospital in Gothenburg
(Figure 1). At follow-up in January 2006, 789 survivors (Stockholm
n¼ 595 and Gothenburg n¼ 194) met the eligibility criteria, that
is, born 1927 or later, being able to read and understand Swedish,
and having no recurrent disease. Eligible survivors received an
introductory letter. Medical records were reviewed to confirm the
cancer diagnosis, stage of disease and treatment techniques
regarding surgery, radiation therapy and chemotherapy.
1800 Identified gynaecological cancer patients treated
with external pelvic radiotherapy, between the years
1991 and 2003 at Karolinska University Hospital,
Stockholm or Sahlgrenska University Hospital,
Gothenburg (perfect person-time)
An introductory letter was sent to 789 eligible survivors
(targeted person-time)
37 Refused to participate without reason




697 (88%) Survivors gave informed oral consent and
were sent a questionnaire
Flow-chart for study population
616 (78%) Survivors returned a questionnaire and
participated in the project
81 Survivors did not complete the study:
52 Agreed but did not return the questionnaire
29 Sent back an empty questionnaire
486 Control women from the Swedish Population
Registry matched for age and residential area
1011 Did not meet the eligibility criteria:
497 Dead at follow-up
436 Born before 1927
23 Could not understand/read Swedish
53 Had recurrence
2 Had not received pelvic radiation therapy
8 Did not meet the eligibility criteria:
Born before 1927
Could not understand/read Swedish
Had received pelvic radiation therapy
Reasons for non-participation in the project:





2 Family members said no
An introductory letter was sent to 478 eligible controls
420 (88%) Controls gave informed oral consent and
were sent a questionnaire 
76 Controls did not complete the study:
66 Agreed but did not return the questionnaire
10 Sent back empty questionnaire
344 (72%) Controls returned a questionnaire and
participated in the project
Figure 1 Flow chart for study population.
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As controls, we recruited 478 women from the Swedish
Population Register, matched for age and residency and who had
not had pelvic radiation therapy (Figure 1). An error in the
matching procedure led to a younger control population (median
age 57.5) compared with the cancer survivors (median age 66.0),
which was adjusted for in the statistical analyses. The Regional
Ethics Committee at the Karolinska Institute approved the study.
Questionnaire
Our methods for studies of cancer survivorship and development
of study-specific questionnaires have been documented in 480
scientific papers (Bergmark et al, 1999; Steineck et al, 2006). A
description of the development and validation of the present
questionnaire has previously been reported (Dunberger et al,
2010). In summary, the questionnaire was developed during an 18
months long qualitative phase including semi-structured inter-
views with 26 gynaecological cancer survivors previously treated
with pelvic radiation therapy. A study-specific questionnaire was
constructed consisting of 351 questions covering symptoms from
the gastrointestinal tract, urinary bladder, genitals, pelvic bones,
abdomen and legs. Questions concerning demographics, sexual
function, intercurrent diseases, psychological and quality-of-life
issues were included. In each part of the questionnaire, we asked
about the incidence, prevalence, intensity and duration of the
symptoms and their impact on different aspects of social
functioning.
Face-to-face validation of the final version was made to ensure
that it was conceivable and had satisfactory internal consistency.
Participation rate and rate of missing values were tested in a pilot
study. The main study, the quantitative phase, was carried out
during January–October 2006. Eligible women who gave informed
consent received a postal questionnaire. Confidentiality was
maintained by numbering the questionnaires.
Radiation therapy
Treatment was administered according to local treatment pro-
grammes and applied study protocols that were ongoing at the
time of treatment. External beam radiation therapy (EBRT) was
based on computed tomography (CT) scans performed before
radiation therapy. Computed tomography scans were made in
treatment position on a flat table top, using laser markers and
conversion factors to electron density. Computed tomography
slices ranged from 5 to 20 mm. The EBRT dose was prescribed
either at isocenter or as mean dose to the target covering at least
95% of the planning target volume (ICRU, 1993). Patients were
treated in supine position, using linear accelerators or a racetrack
accelerator with two opposing fields or a four-field box technique.
Daily dose per fraction varied between 1.6 and 2.0 Gy. External
beam radiation therapy was verified by portal image films and with
check-and-confirm systems. Brachytherapy (BT) was applied using
standardised techniques and applicator templates. The BT dose
was prescribed according to local practice. Pre-treatment ortho-
gonal X-ray images verified the position of the BT applicator.
A detailed description of treatment techniques in relation
to cancer diagnosis is provided in the Supplementary Appendix
Table A1. For radiograph figures of typical treatment; see the
Supplementary Appendix Figures A1–A4.
Statistical analyses
The results from the questionnaire and the data from the medical
records were coded and transferred to the freeware data-entry
program Epi-Data (http://www.epidata.dk). We used Fisher’s exact
test (Monte Carlo approximation, 107 samples) to test for
differences in survivors and control characteristics (Table 1).
The test was two-sided and at the 5% significance level.
Different cut-off levels were used to describe the frequency of
symptom occurrence. For initial analyses, a symptom was
dichotomised into having the symptom occasionally or more
often and into not having the symptom at all the past 6 months. In
the final analyses, the cut-off level was changed into at least once a
week in symptoms that had a high prevalence, that is, exceeding
45% in controls. We calculated the proportions having each
outcome (symptom) among cancer survivors and control women,
and used relative risk (RR) defined as the ratio between these
proportions as outcome measure. Age-adjusted RRs with 95%
confidence intervals (CIs) were calculated according to the log-
binomial model (McNutt et al, 2003) including age as a categorical
covariate with the categorisation used in Table 1. Individuals with
missing data were excluded from the calculations of each
respective outcome. All calculations were performed using the
SAS statistical software package (version 9.2, SAS Institute Inc.,
Cary, NC, USA).
RESULTS
In all, 616 of 789 (78%) cancer survivors and 344 of 478 (72%)
control women returned a completed questionnaire and partici-
pated in the study (Figure 1). Median follow-up time was 74
months with a range of 26 –179 months.
The median age for cancer survivors was 66.0 years and for
control women 57.5 years (Table 1). Cancer survivors were more
often single, had a lower level of education, lower degree of
physical activity and were more often on disability pension
compared with control women.
Nulliparity was twice as common among the survivors.
Operational procedures at delivery and vaginal or perineal injury
were less common among cancer survivors. The most common
co-morbidity among cancer survivors was hypertension occurring
in 38%, compared with 27% in control women. Diabetes mellitus
and heart failure were also more prevalent among cancer
survivors. Endometrial cancer and cervical cancer were the most
common diagnoses. In all, 84% of the cancer survivors were
treated for stage I– II disease.
Overall 90% of the gynaecological cancer survivors were treated
with surgery and EBRT with or without BT and chemotherapy. The
remaining 10% consisted of a subset of cervical and vaginal cancer
patients treated with radiation therapy alone (Figure 2). Additional
information on demographic and clinical characteristics as well as
a detailed description of treatment in relation to cancer diagnosis
is provided in the Supplementary Appendix Table A1 and
Supplementary Appendix Table A2. Treatment schedules for
ovarian and fallopian tube cancer were identical and the results
are hence presented together.
Symptoms associated with cancer therapy
With a median follow-up time of 6.2 years, cancer survivors
reported a higher occurrence of symptoms from the anal sphincter,
the bowel, the urinary tract, symptoms related to sexuality, the
pelvic bones and the lower abdomen and legs, compared with
control women (Table 2 and Supplementary Appendix A3).
The highest age-adjusted RR among anal-sphincter symptoms
was for ‘emptying of all stools into clothing without forewarning’,
RR 12.7 (95% CI 4.0– 40.3) with a prevalence of 12% among
survivors and 0.9% among control women. This symptom was
reported by one-third of the survivors with uterine sarcoma
compared with 9% among survivors with endometrial and ovarian
cancer. The prevalence of symptoms in relation to diagnosis is
provided in the Supplementary Appendix Table A4. The occur-
rence of symptoms from the anal sphincter and bowel was in
general higher among survivors with uterine sarcoma, cervical and
vaginal cancer compared with endometrial and ovarian cancer
survivors.
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The highest age-adjusted RRs among urinary tract symptoms
were observed for ‘difficulty feeling the need to empty the bladder’
(RR 2.8; 95% CI 1.5– 5.4) with a prevalence of 9% in survivors
compared with 3% in control women. The corresponding figures
for ‘difficulty feeling a full bladder’ (RR 2.7; 95% CI 1.6–4.5), was
15% in cancer survivors compared with 5% in control women.
These symptoms occurred more frequently among survivors
treated with radiation therapy alone compared with those treated
with surgery and radiation therapy.
For symptoms related to sexuality, 34% of the survivors
reported ‘absence of vaginal elasticity’ compared with 14% among
control women (RR 1.8; 95% CI 1.3–2.4). This symptom occurred
in 47% of survivors treated with radiation therapy alone. ‘Deep
dyspareunia when having intercourse’ occurred in 17% of cancer
survivors irrespective of treatment modality, compared with 7%
among control women (RR 3.7; 95% CI 2.4– 5.7). About one-third
of the survivors reported a ‘decreased ability for intercourse
leading to a lower intercourse frequency’.
Pubic bone pain was at least three times as common among
survivors compared with control women. The highest age-adjusted
RR was for ‘pubic pain when walking indoors’, RR 4.9 (95% CI
2.1–11.6). Among survivors treated with radiation therapy alone,
this symptom was reported by 18% compared with 2% among
control women (RR 10.3; 95% CI 4.0–26.7).









28–49 64/616 (10) 102/342 (30)
50–59 102/616 (17) 80/342 (23)
60–69 233/616 (38) 78/342 (23)
70–79 217/616 (35) 82/342 (24)
Median age, years (range) 66.0 (28–79) 57.5 (36–79)
Marital status 0.009
Married or living with a partner 344/613 (56) 220/344 (64)
Has a partner but lives alone 37/613 (6) 22/344 (6)
Widow 84/613 (14) 37/344 (11)
Single 148/613 (24) 65/344 (19)
Education o0.001
Elementary school 196/615 (32) 69/342 (20)
Secondary school 236/615 (38) 146/342 (43)
College or university 183/615 (30) 127/342 (37)
Employment o0.001
Student 5/613 (o1) 2/343 (o1)
Unemployed 12/613 (2) 6/343 (2)
Employed 202/613 (33) 188/343 (55)
Housewife, other 11/613 (2) 5/343 (1)
On sick leave 11/613 (2) 10/343 (3)
Disability pension 53/613 (9) 15/343 (4)
Retired 319/613 (52) 117/343 (34)
Country of birth o0.001
Sweden 510/614 (83) 316/344 (92)
Place of residency 0.402
Rural district 52/615 (10) 34/341 (10)
Village/town 191/615 (31) 93/341 (27)
4500 000 citizen 372/615 (60) 214/341 (63)
Smoking 0.608
Current smoker 144/607 (24) 88/343 (26)
Former smoker 183/607 (30) 108/343 (31)
Never smoker 280/607 (46) 147/343 (43)
BMIb 0.256
o18.5 (underweight) 16/575 (3) 5/327 (2)
18.5–25.0 (normal weight) 261/575 (45) 163/327 (50)
25.0–30.0 (overweight) 201/575 (35) 116/327 (35)
430.0 (obese) 97/575 (17) 43/327 (13)
BMI, median (range) 25.1 (16.0–53.1) 24.7 (13.4–44.5)
Exercise 0.001
Never 76/599 (13) 20/341 (6)
Occasionally – at least
once a month
78/599 (13) 59/341 (17)
At least once a week 445/599 (74) 262/341 (77)
Parity o0.001
Nulli (never given birth) 154/615 (25) 45/344 (13)
1–3 para 410/615 (67) 280/344 (81)
43 para 51/615 (8) 19/344 (6)
Delivery
Fast o5 h 250/607 (41) 147/342 (43) 0.631
Slow 424 h 141/607 (23) 88/342 (26) 0.386
Vacuum 41/607 (7) 43/342 (13) 0.004
Forceps 12/607 (2) 7/342 (2) 1.000
Episiotomy 132/607 (22) 117/342 (34) o0.001
Caesarean 28/607 (5) 40/342 (12) 0.001
Breech birth 18/607 (3) 20/342 (6) 0.038







Delivery with birth weight 44 kg 0.266
1 78/612 (13) 54/344 (16)
X2 42/612 (7) 29/344 (8)
Pelvic floor injury
Vaginal or perineal injury 111/599 (19) 101/342 (30) o0.001
Anal sphincter injury 18/593 (3) 18/342 (5) 0.111
Intercurrent diseases
Previous abdominal surgery 264/616 (43) 156/344 (45) 0.456
Diabetes mellitus 58/611 (9) 17/338 (5) 0.016
Angina pectoris 32/600 (5) 11/341 (3) 0.147
Cardiac infarction 18/600 (3) 5/341 (1) 0.188
Heart failure 33/600 (6) 8/341 (2) 0.029
Hypertension 227/600 (38) 91/341 (27) o0.001
Crohn’s disease, treatment for 1/594 (o1) 0/332 (0) 1.000
Ulcerative colitis, treatment for 5/581 (o1) 7/327 (2) 0.131
Irritable bowel syndrome,
treatment for
27/594 (4) 13/332 (4) 0.737
Haemorrhoids, treatment for 61/591 (10) 45/322 (14) 0.105
Lactose intolerance 33/598 (6) 13/331 (4) 0.334
Gluten intolerance 8/604 (1) 3/330 (o1) 0.755
Pelvic organ prolapse,
treatment for
12/596 (2) 13/332 (4) 0.094
Rheumatism 37/600 (6) 19/341 (6) 0.775
Kidney disease 19/600 (3) 8/341 (2) 0.546
Lung disease 40/600 (7) 12/341 (4) 0.053
Thrombosis 47/600 (8) 16/341 (5) 0.077
Osteoporosis 58/600 (10) 25/341 (7) 0.235
Psychological disorders 78/600 (13) 43/341 (13) 0.919
Neurological disordersc 15/600 (3) 3/341 (o1) 0.089
Medication
Using any kind of medication 439/606 (72) 194/338 (57) o0.001
Oestrogen 224/606 (37) 50/339 (15) o0.001
Abbreviation: BMI¼ body mass index. Denominator is dependent on number of
respondents answering a specific item and may differ from the maximum sum.
Percentage may not total hundred because of rounding. aP-value according to Fisher’s
exact test. bCurrent BMI at the time the questionnaire was completed. cParkinson’s
disease, multiple sclerosis and epilepsy.
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For the abdomen and legs the highest age-adjusted RR was for
‘erysipelas on abdomen or legs’, RR 3.6 (95% CI 1.0–12.8) followed
by ‘lower abdominal heaviness’, RR 2.1 (95% CI 1.5– 3.0) occurring
in one-fifth of the survivors. The prevalence among survivors
treated with radiation therapy alone was 30%, compared with 11%
among control women.
DISCUSSION
Gynaecological cancer survivors treated with pelvic radiation
therapy alone or as part of combined treatment reported higher
occurrence of late specific symptoms from all normal tissues
addressed in the study, that is, the anal sphincter, the bowel, the
urinary tract, the pelvic bones, the lower abdomen and legs as well
as symptoms related to sexuality compared with matched control
women.
Although gastrointestinal side-effects following pelvic radiation
therapy are well documented, the occurrence and specificity of
anal sphincter and bowel symptoms in long-term survivors have
been less well studied (Andreyev, 2005; Putta and Andreyev, 2005).
We have in a previous publication reported on our findings of
higher occurrence of gastrointestinal symptoms and a 12-fold
higher occurrence of emptying of all stools into clothing without
forewarning among long-term gynaecological cancer survivors
compared with controls. This severe faecal incontinence symptom
was more prevalent in survivors treated for cervical cancer and
uterine sarcoma. These diagnoses had in general higher median
EBRT doses. In a previous study from our group, 65 prostate
cancer survivors were asked by means of a study-specific postal
questionnaire about bowel and urinary symptoms and sexual
function 2– 4 years after curative EBRT to the prostate. A
correlation was found between the dose to the anal sphincter
and faecal leakage in the interval of 45–55 Gy and also a
correlation between defaecation urgency and loose stools and the
dose to the rectum in the interval of 25–42 Gy (al-Abany et al,
2005). It is reasonable to also investigate the impact of dose to
bowel and anal sphincter in relation to the occurrence of emptying
of all stools without forewarning.
The urinary bladder has been regarded as less radiosensitive
compared with the bowel (Marks et al, 1995). Late urinary side-
effects appear to be less common but there are few published
reports on the prevalence of specific urinary symptoms among
long-term gynaecological cancer survivors. With median follow-up
of 60 and 68 months, the PORTEC-1 trial reported a prevalence of
8% of mild genitourinary complications (measured by French-
Italian glossary), while the GOG99 trial reported a 25% genitour-
inary complication rate (assessed by the 1985 GOG Adverse Events
Criteria scale) after postoperative EBRT in women with early
stages of endometrial cancer (Creutzberg et al, 2001; Keys et al,
2004). In the PORTEC-1 trial, the complications consisted of
urinary urgency, recurrent urinary infections and minor incon-
tinence while no details on specific symptoms are specified in the
GOG 99 trial report. A higher risk of late urinary side-effects is
reported for cervical cancer, which may be related to the higher
doses of radiation therapy used (Elliott and Malaeb, 2011). In an
observational study by Pieterse et al (2006), no increased
occurrence of bladder dysfunction was reported at 24 months’
follow-up in 94 early-stage cervical cancer patients treated with
postoperative EBRT, compared with surgery alone or control
women. Nearly, every study shows that late post-radiation urinary
morbidity continues to progress decades after radiation therapy.
The short follow-up period and the restriction to only two
questions concerning micturition may have contributed to the
results reported by Pieterse et al (2006). In a population-based
survey of 291 cervical cancer survivors with an average follow-up
period of 6.6 years, self-reported symptoms of frequent micturition
were reported by 42 and 45% following radiation therapy alone or
postoperative EBRT (Korfage et al, 2009). Urinary leakage was
reported by 19 and 26% and difficulties emptying the bladder in
6% and 11%, respectively. These results are in line with our
findings. Besides difficulties emptying the bladder, urinary
incontinence, urgency and cystitis, the survivors in our study also
reported difficulties feeling a full bladder. Our results indicate that
late side-effects from the urinary tract following radiation therapy
are underestimated and underreported.
Most previous population-based surveys addressing the impact
of radiation therapy on normal tissues have focused on sexuality in
survivors after treatment of cervical cancer. In a population-based
cohort study of long-term early stage cervical cancer, survivors
reported more sexual dysfunction resulting in considerable
distress, compared with control women (Bergmark et al, 1999).
The impact of radiation therapy on sexual function has since then
been confirmed in several publications (Jensen et al, 2003;
Frumovitz et al, 2005; Park et al, 2007; Korfage et al, 2009). Some



































































Figure 2 Treatment modality dependent on diagnosis. Abbreviations: Surg¼ surgery; EBRT¼ external beam radiation therapy; BT¼ brachytherapy;
chemo¼ chemotherapy.
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Emptying of all stools into clothing without
forewarning at least occasionally
70/606 (12) 3/344 (0.9) 12.7 (4.0–40.3) 55/546 (10) 8.8 (2.8– 28.3) 15/60 (25) 30.3 (9.1– 101.1)
Leakage of loose stools while awake at least occasionally 199/608 (33) 18/344 (5) 6.0 (3.7–9.6) 171/545 (31) 5.5 (3.4– 8.8) 28/63 (44) 8.5 (5.0– 14.5)
Leakage of loose stools while asleep at least occasionally 72/611 (12) 8/343 (2) 5.5 (2.6–11.4) 58/548 (11) 4.4 (2.1– 9.2) 14/63 (22) 9.8 (4.3– 22.4)
Anal leakage of mucus while asleep at least occasionally 32/607 (5) 4/344 (1) 4.9 (1.7–14.1) 25/545 (5) 3.3 (1.1– 9.4) 7/62 (11) 9.7 (2.9– 32.3)
Leakage of solid stools while awake at least occasionally 46/607 (8) 5/344 (1) 4.4 (1.7–11.0) 37/544 (7) 3.4 (1.4– 8.7) 9/63 (14) 9.3 (3.2– 27.0)
Faecal leakage without forewarning despite previous
defaecation at least occasionally
188/605 (31) 23/344 (7) 4.2 (2.8–6.4) 168/545 (31) 3.9 (2.6– 6.0) 20/60 (33) 4.8 (2.8– 8.2)
Defaecation urgency with faecal leakage at least
occasionally
298/603 (49) 42/343 (12) 4.0 (3.0–5.4) 262/541 (48) 3.8 (2.8– 5.2) 36/62 (58) 4.8 (3.3– 6.8)
Foul smelling flatulence at least once a week 116/602 (19) 22/343 (6) 3.7 (2.4–5.8) 102/541 (19) 3.8 (2.4– 5.9) 14/61 (23) 3.6 (2.0– 6.7)
Anal leakage of mucus while awake at least occasionally 87/603 (14) 14/343 (4) 3.5 (2.0–6.1) 76/542 (14) 3.2 (1.8– 5.6) 11/61 (18) 4.1 (1.9– 8.6)
Self-perception of faecal odour at least occasionally 108/606 (18) 18/340 (5) 3.3 (2.0–5.4) 95/544 (17) 3.1 (1.9– 5.2) 13/62 (21) 4.0 (2.1– 7.8)
Involuntary flatulence at least once a week 127/606 (21) 33/343 (10) 2.4 (1.7–3.5) 111/545 (20) 2.3 (1.5– 3.3) 16/61 (26) 2.8 (1.7– 4.8)
Unwanted defaecation while emptying bladder at least
occasionally
238/603 (39) 57/342 (17) 2.4 (1.9–3.2) 213/541 (39) 2.4 (1.8– 3.1) 25/62 (40) 2.3 (1.6– 3.4)
Anal leakage of blood while awake at least occasionally 42/608 (7) 12/343 (4) 2.0 (1.1–3.9) 37/545 (7) 2.0 (1.0 – 3.9) 5/63 (8) 2.2 (0.8 –6.7)
Involuntary loud flatulence at least occasionally 359/607 (59) 150/344 (44) 1.4 (1.2–1.6) 314/546 (58) 1.3 (1.1– 1.5) 45/61 (74) 1.7 (1.4– 2.1)
Bowel symptoms
Defaecation urgency at least once a week 175/602 (29) 19/341 (6) 5.7 (3.5–9.1) 157/542 (29) 5.7 (3.5– 9.1) 18/60 (30) 6.0 (3.3– 10.8)
Protracted abdominal pain lasting 41 year, yes 69/593 (12) 15/339 (4) 3.2 (1.9–5.6) 59/532 (11) 3.1 (1.7– 5.5) 10/61 (16) 3.8 (1.8– 7.9)
Loose stools at least once a week 234/602 (39) 48/344 (14) 3.0 (2.2–3.9) 205/540 (38) 2.9 (2.1– 3.9) 29/62 (47) 3.5 (2.4– 5.1)
Abdominal pain and vomiting at least occasionally 60/605 (10) 13/344 (4) 2.6 (1.4–4.7) 49/545 (9) 2.2 (1.2– 4.1) 11/60 (18) 4.8 (2.2– 10.1)
Mucus in stools at least occasionally 156/607 (26) 45/343 (13) 2.1 (1.5–3.0) 143/545 (26) 2.2 (1.6– 3.0) 13/62 (21) 1.6 (0.9 –2.8)
Abdominal bloating at least once a week 147/605 (24) 60/342 (18) 1.8 (1.4–2.3) 129/544 (24) 1.8 (1.3– 2.3) 18/61 (30) 1.8 (1.1– 2.7)
Rectal bleeding at least occasionally 103/604 (17) 42/341(12) 1.6 (1.1–2.2) 92/545 (17) 1.6 (1.2– 2.4) 11/59 (19) 1.5 (0.8 –2.8)
Abdominal pain and stools at least occasionally 198/602 (33) 79/343 (23) 1.6 (1.3–2.0) 171/541 (32) 1.5 (1.2– 1.9) 27/61 (44) 2.0 (1.4– 2.8)
Abdominal pain at least occasionally 307/604 (51) 137/340 (40) 1.4 (1.2–1.6) 272/544 (50) 1.4 (1.2– 1.6) 35/60 (58) 1.5 (1.2– 1.9)
Abdominal pain and bloating at least occasionally 228/603 (38) 106/340 (31) 1.4 (1.2–1.7) 199/542 (37) 1.4 (1.2– 1.7) 29/61 (48) 1.6 (1.2– 2.1)
Urinary tract symptoms
Difficulty feeling the need to empty bladder at least
occasionally
56/604 (9) 11/343 (3) 2.8 (1.5–5.4) 46/544 (8) 2.5 (1.3– 5.0) 10/60 (17) 5.1 (2.3– 11.3)
Difficulty emptying bladder at least occasionally 49/602 (8) 11/343 (3) 2.7 (1.4–5.2) 43/542 (8) 2.7 (1.4– 5.5) 6/60 (10) 3.2 (1.3– 8.4)
Difficulty feeling full bladder at least occasionally 90/602 (15) 18/342 (5) 2.7 (1.6–4.5) 76/543 (14) 2.4 (1.4– 4.1) 14/59 (24) 4.5 (2.4– 8.4)
Haematuria at least occasionally 20/606 (3) 5/344 (1) 2.5 (0.9 – 6.9) 16/546 (3) 2.4 (0.8 – 6.8) 4/60 (7) 5.0 (1.4– 17.8)
Straining to initiate emptying of bladder at least
occasionally
77/605 (13) 21/343 (6) 2.2 (1.4–3.7) 68/545 (12) 2.4 (1.5– 3.9) 9/60 (15) 2.5 (1.2– 5.3)
Painful emptying of bladder at least occasionally 60/605 (10) 20/341 (6) 2.0 (1.2–3.3) 52/545 (10) 1.9 (1.1– 3.3) 8/60 (13) 2.3 (1.1– 5.0)
Urinary incontinence without urinary urgency at
least occasionally
88/603 (15) 24/342 (7) 1.8 (1.2–2.9) 81/543 (15) 1.9 (1.2– 3.0) 7/60 (12) 1.6 (0.7 –3.6)
Night-time emptying of bladder at least twice per
night or more, yes
222/607 (37) 58/341 (17) 1.8 (1.4–2.4) 199/548 (36) 1.8 (1.4– 2.4) 23/59 (39) 2.2 (1.5– 3.2)
Need of antibiotics because of urinary tract infection
twice or more, yes
93/605 (15) 31/344 (9) 1.6 (1.1–2.3) 86/545 (16) 1.7 (1.1– 2.5) 7/60 (12) 1.3 (0.6 –2.9)
Urinary incontinence because of urinary urgency
at least occasionally
209/607 (34) 66/342 (19) 1.6 (1.2–2.0) 186/545 (34) 1.5 (1.2– 2.0) 23/62 (37) 1.8 (1.2– 2.7)
Slow emptying of bladder at least occasionally 122/605 (20) 47/344 (14) 1.6 (1.2–2.2) 106/546 (19) 1.5 (1.1– 2.2) 16/59 (27) 2.0 (1.2– 3.3)
Self-perception of urine odour at least occasionally 149/605 (25) 62/341(18) 1.4 (1.1–1.9) 126/544 (23) 1.3 (1.0– 1.8) 23/61 (38) 2.1 (1.4– 3.0)
Urinary urgency at least occasionally 346/605 (57) 139/343 (41) 1.3 (1.1–1.5) 308/544 (57) 1.3 (1.1– 1.5) 38/61 (62) 1.5 (1.2– 1.8)
Feeling of incomplete bladder emptying at least
occasionally
232/604 (38) 101/343 (29) 1.3 (1.1–1.6) 203/544 (37) 1.3 (1.0– 1.6) 29/60 (48) 1.6 (1.2– 2.2)
Symptoms related to sexuality
Protracted genital pain lasting for 41 year, yes 28/593 (5) 4/339 (1) 5.0 (1.7–14.5) 21/532 (4) 4.3 (1.4– 13.0) 7/61 (11) 9.6 (2.9– 31.8)
Genital bleeding during or after intercourse at
least once, yes
54/585 (9) 13/329 (4) 3.7 (2.1–6.7) 45/523 (9) 3.6 (2.0– 6.7) 9/62 (15) 3.9 (1.8– 8.4)
Deep dyspareunia when having intercourse,
at least a little
101/583 (17) 23/330 (7) 3.7 (2.4–5.7) 90/521 (17) 3.7 (2.4– 5.8) 11/62 (18) 3.0 (1.6– 5.7)
Vaginal lubrication when sexually aroused, no 39/577 (7) 7/333 (2) 2.9 (1.3–6.4) 37/517 (7) 2.9 (1.3– 6.5) 2/60 (3) 1.6 (0.3 –7.5)
Decreased ability for intercourse leading to lower
intercourse frequency, at least a little
176/575 (31) 37/327 (11) 2.9 (2.1–4.1) 160/515 (31) 2.9 (2.0– 4.0) 11/60 (18) 2.5 (1.5– 4.1)
Vaginal elasticity, no 172/502 (34) 41/302 (14) 1.8 (1.3–2.4) 148/451 (33) 1.6 (1.2– 2.2) 24/51 (47) 2.5 (1.7– 3.7)
Genital swelling when sexually aroused, no 82/571 (14) 35/327 (11) 1.5 (1.0–2.2) 72/512 (14) 1.5 (1.0 – 2.2) 10/59 (17) 1.6 (0.9 –3.1)
Superficial dyspareunia when having intercourse,
at least a little
140/584 (24) 67/330 (20) 1.5 (1.2–2.0) 125/523 (24) 1.5 (1.1– 2.0) 15/61 (25) 1.4 (0.8 –2.2)
Sensitivity to touch inside vagina, no 221/540 (41) 65/310 (21) 1.3 (1.0–1.6) 192/485 (40) 1.2 (1.0 – 1.5) 29/55 (53) 1.7 (1.3– 2.2)
Sensitivity to touch of labia and clitoris, no 186/558 (33) 61/320 (19) 1.2 (0.9 – 1.5) 163/501 (33) 1.1 (0.9 – 1.4) 23/57 (40) 1.5 (1.1– 2.1)
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prevent development of vaginal stenosis following radiation
therapy as reviewed by the Cochrane Collaboration (Denton and
Maher, 2003).
We have in a previous publication reported on the findings of
higher occurrence of pubic bone symptoms and increased
frequency of pubic bone pain with mean absorbed dose exceeding
52.5 Gy to the pubic bone (Waldenström et al, 2010). Cancer
survivors in our study treated with radiation therapy alone also
reported a higher prevalence of hip pain. The potential relation-
ship between hip pain and radiation dose will be addressed in a
coming report from our group.
Lymph oedema is a common late symptom among gynaecolo-
gical cancer survivors (Bergmark et al, 2006). In a population-
based mailed survey of 802 gynaecological cancer survivors
(Beesley et al, 2007), 25% were diagnosed with lymph oedema or
had symptomatic lower limb swelling. A higher prevalence was
observed in vulvar cancer survivors. These results are consistent
with our findings. The survivors in our study also report a higher
occurrence of heaviness or swollen lower abdomen. The prevalence
was higher after radiation therapy alone than after combination of
surgery and radiation therapy. One may speculate that fibrosis or
occlusion of lymph vessels after radiation therapy may be involved
in the mechanism behind this symptom.
Some of the strengths of this study are the large population-
based patient cohort and the high participation rate. Access to all
medical records has ensured correct information regarding clinical
characteristics and detailed knowledge of administered treatment.
The construction of the study-specific questionnaire in close
cooperation with the gynaecological cancer survivors, comprehen-
sive face-to-face validation and the use of a privately answered
questionnaire lowered the risk for measurement errors and
eliminated interviewer-induced bias. By asking for symptom
occurrence during the past 6 months, we avoided capturing
temporary symptoms produced by chance and at the same time
minimised risk of recall-induced problems. Symptoms were
atomised, subdivided into very specific questions, which may
have contributed to survivors’ multitude of symptoms. In an effort
to increase participation, we did not include subjects over the age
of 80 years. We cannot, however, exclude the possibility that non-
participating subjects would have answered differently. The loss of
information from part of the targeted-person-time may result in a
deviation between the true effect measure and the observed effect
measure in a way that is unpredictable. The minimum internal
response rate for individual questions was 81% (502 out of 616) for
survivors and 88% (302 out of 344) for control women in questions
dealing with sexuality. This may negatively affect the generalisa-
bility of the study result. Individuals who failed to respond to a
certain question were excluded from the analysis of that outcome.
In all tables, the response rates can be assessed through the
denominator that is presented for all items.
Research regarding long-term treatment effects in cancer
survivors will give us knowledge for developing new strategies in
cancer treatment. Updated recommendations are gradually intro-
duced into clinical use. Several randomised clinical trials
investigating the outcome of adjuvant radiation therapy in
endometrial cancer patients have shown an increased risk of late
radiation therapy-induced morbidity but without survival benefit
(Creutzberg et al, 2001; Keys et al, 2004; Nout et al, 2009). Hence,
adjuvant radiation therapy is nowadays seldom given to endo-
metrial patients with low-intermediate risk malignancy. A
potential new treatment approach is TGF-b, which is a promising
target for preventing radiotherapy-induced fibrosis (Anscher,
2010). In addition, we also believe that prevention of some
symptoms may be achieved by optimising radiation delivery by
improved target imaging and treatment planning with dose-
constraints guidelines and by the use of intensity modulated
radiation therapy (Small et al, 2008).
In this first stage of our gynaecological cancer survivorship
programme, we report on the occurrence of symptoms from
normal tissues after pelvic irradiation. In the second stage of our
programme, we will continue the reporting of the impact of
specific symptoms on daily life activities and quality of life. The





























Pubic pain when walking indoors at
least occasionally
46/603 (8) 6/343 (2) 4.9 (2.1– 11.6) 35/542 (6) 4.1 (1.7– 10.2) 11/61 (18) 10.3 (4.0–26.7)
Pubic pain when walking outdoors 500 m at
least occasionally
42/596 (7) 7/343 (2) 3.7 (1.7– 8.4) 34/536 (6) 3.3 (1.4– 7.7) 8/60 (13) 6.6 (2.5–17.5)
Pubic pain, yes 67/603 (11) 12/339 (4) 3.4 (1.9– 6.4) 53/544 (10) 3.0 (1.6– 5.7) 14/59 (24) 7.0 (3.5–14.2)
Hip pain, yes 212/599 (35) 113/343 (33) 1.0 (0.8 – 1.2) 182/538 (34) 0.9 (0.8 – 1.2) 30/61 (49) 1.5 (1.1–2.0)
Hip pain when walking outdoors 500 m at least
occasionally
193/598 (32) 102/340 (30) 1.0 (0.8 – 1.3) 165/536 (31) 1.0 (0.8 – 1.2) 28/62 (45) 1.5 (1.1–2.0)
Sacral pain, yes 232/600 (39) 179/344 (52) 0.8 (0.7– 0.9) 196/539 (36) 0.7 (0.6– 0.8) 36/61 (59) 1.1 (0.9 –1.4)
Lower abdomen and leg symptoms
Erysipelas on abdomen or legs, yes 17/597 (3) 3/336 (1) 3.6 (1.0– 12.8) 14/537 (3) 4.0 (1.1– 14.5) 3/60 (5) 5.2 (1.1–25.1)
Lower abdominal heaviness at least occasionally 119/600 (20) 38/344 (11) 2.1 (1.5– 3.0) 101/540 (19) 2.1 (1.4– 3.0) 18/60 (30) 2.7 (1.7–4.5)
Pain in lower abdomen in connection with
oedema at least occasionally
92/607 (15) 33/343 (10) 1.9 (1.3– 2.8) 75/546 (14) 1.7 (1.1– 2.6) 17/61 (28) 3.0 (1.8–5.0)
Leg pain in connection with oedema at
least occasionally
164/606 (27) 54/342 (16) 1.7 (1.3– 2.3) 145/545 (27) 1.7 (1.2 (2.2) 19/61 (31) 2.0 (1.3–3.2)
Swollen lower abdomen at least occasionally 121/599 (20) 51/342 (15) 1.7 (1.3– 2.4) 106/538 (20) 1.8 (1.3– 2.5) 15/61 (25) 1.7 (1.0–2.8)
Protracted leg pain lasting 41 year, yes 134/593 (23) 48/339 (14) 1.5 (1.1– 2.1) 115/532 (22) 1.4 (1.0– 2.0) 19/61 (31) 2.2 (1.4–3.4)
Swollen legs at least occasionally 218/606 (36) 94/344 (27) 1.4 (1.1– 1.7) 197/546 (36) 1.4 (1.1– 1.9) 21/60 (35) 1.4 (0.9 –2.0)
Heavy legs at least occasionally 210/606 (35) 97/344 (28) 1.1 (1.1– 1.6) 186/546 (34) 1.3 (1.0– 1.6) 24/60 (40) 1.4 (1.0–2.1)
Abbreviations: CI¼ confidence interval; RR¼ relative risk; RT¼ radiation therapy. Bold entries indicate statistic significance. The symptoms are sorted into anatomical region of
supposed origin and in size order for RR, the number in the denominator may vary because of missing information.
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study cohort is highly heterogeneous and these circumstances
contribute to variability of the absorbed dose of ionising radiation
to the normal tissue surrounding the target, which will enable us to
study the dose-volume effects of radiation therapy to normal-
tissues in relation to self-reported symptoms. In the third stage of
our survivorship programme, we intend to explore which levels of
ionising radiation delivered to specific volumes of normal tissue
surrounding the target that contribute to the occurrence of a
specific symptom, which can affect quality of life. This may help
the radiotherapist to optimise dose planning and thereby hopefully
reduce the symptom burden among future long-term gynaecolo-
gical cancer survivors.
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Dörr W, Hendry JH (2001) Consequential late effects in normal tissues.
Radiother Oncol 61: 223 – 231
Dunberger G, Lind H, Steineck G, Waldenström AC, Nyberg T, Al-Abany
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